D&D Pharmatech

At a glance

D&D Pharmatech filed 46 disclosures in the last 12 months, including 12 insider, 1 contract, 1 5% holder and 1 issuance. The most recent key filing was on Sep 8.

Revenue for 2025 was ₩4.3B, down 62.4% on 2024. It made an operating loss of ₩34B. Debt was 24% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩790.8M and operating loss of ₩21B.

The 2025 annual report lists 22 employees with an average tenure of 4.7 years and average pay of ₩169.6M. Its 7 directors and auditors were paid ₩141M each on average. It paid no cash dividend for 2025. 이슬기 and related parties held 20.42% at year end.

From the 2025 annual report

Staff: 22 (9 men, 13 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.7B. Directors and auditors: 7, paid ₩852M in total.

No cash dividend was paid for 2025.

Largest shareholder

이슬기 holds 12.99%; with 10 related parties the group holds 20.42% of common shares at year end (from 20.82% at the start of the year).

Auditor: 이촌회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary